Capital Square 1031 Acquires Medical Office Building Near Raleigh, North Carolina in All-Cash/No Debt DST

January 31, 2017

Capital Square 1031 Acquires Medical Office Building Near Raleigh, North Carolina in All-Cash/No Debt DST

Property is 100 percent occupied by local operator of Fresenius Medical Care, the world’s leading provider of dialysis products and services

January 30, 2017 | Capital Square 1031

RALEIGH, N.C. (Jan. 30, 2017) – Capital Square 1031 announced today that the company has acquired a newly-constructed medical office building located in the Raleigh suburb of Louisburg, North Carolina. The building is 100 percent leased to an affiliate of Fresenius Medical Care, the world’s leading provider of dialysis products and services.

 Located at 935 North Main St., the 8,200-square-foot, single-story building was built-to-suit for Fresenius as a dialysis clinic. The company took occupancy of the property in October 2016, and leases it on a double net basis for a base term of 15 years, plus renewal options.

 “We are pleased to add this medical office building to our growing portfolio of assets under management, which now includes 17 medical office buildings, and has a total value of approximately $571 million, based on investment cost,” said Louis Rogers, founder and chief executive officer of Capital Square 1031. “These clinics are operated by a strong tenant, whose parent company, Fresenius Medical Care AG & Co. KGaA, reported a net revenue of approximately $16.7 billion for fiscal year 2015.”

 The medical office building was acquired on an all-cash, no debt basis as part of a Delaware statutory trust offering, CS1031 Louisburg MOB, DST.

 Rogers added, “This is Capital Square’s 36th DST offering and the third all-cash, no debt DST offering, which is a fairly new phenomenon for 1031 exchange investors that prefer a debt-free replacement property.”

 Listed on both the Frankfurt Stock Exchange (DAX: FME) and New York Stock Exchange (NYSE: FMS), Fresenius is engaged in providing kidney dialysis services and clinical laboratory testing; manufacturing and distributing products and equipment for kidney dialysis treatment; and providing other medical ancillary services. During the fiscal year 2015, Fresenius posted revenues of approximately $16.7 billion. The company also cared for in excess of 294,000 dialysis patients in 3,418 proprietary clinics located in more than 45 countries worldwide. Fresenius operates more than 40 production sites, which makes it the leading provider of dialysis products, including dialysis machines, dialyzers and disposable accessories.

About Capital Square 1031

Capital Square 1031 is a national real estate investment and management company. The firm sponsors institutional-quality real estate exchange programs that qualify for tax deferral under Section 1031 of the Internal Revenue Code. Capital Square uses the Delaware Statutory Trust (DST) structure to make quality real estate available to a larger number of investors. Capital Square provides a range of services, including due diligence, acquisition, loan sourcing, property management/asset management, and disposition, for a growing number of high net worth investors, private equity firms, family offices and institutional investors. As of January 26, 2017, the firm oversees a national portfolio of 57 real estate assets valued at approximately $571 million (based on investment cost). In September 2016, Capital Square was ranked as the second fastest growing company in the Richmond, Virginia area by Richmond BizSense, with 274 percent annual revenue growth from 2013 to 2015. To learn more, visit www.CapitalSquare1031.com.


Kind regards, 

Julie Leber

Spotlight Marketing Communications

949.427.5172, ext. 703


Print Friendly, PDF & Email
Go Back
Gil Armour, CFP
February 3, 2016

I have been using Blue Vault Partners for the past five years.  I have found them to be a valuable, unbiased resource when it comes to evaluating and comparing non-traded REITs.  The reports help me analyze which sponsors are doing a responsible job of managing their offerings.  This allows me to limit my REIT recommendations to only the most competitive products, and then track those REITs throughout their life cycle.